BACKGROUND: A critical factor for successful organ preservation treatment in head and neck cancer may be selecting tumors that respond to chemotherapy and radiation. Previous results in patients indicated that tumors that overexpressed p53 were more sensitive to chemotherapy than those that did not overexpress p53. METHODS: To determine the relationship of p53 mutations to sensitivity to cisplatin in vitro, 23 head and neck squamous cell carcinoma (HNSCC) cell lines were analyzed for cisplatin sensitivity, p53 expression, and p53 mutation status. RESULTS: Mutations of the p53 gene were identified in 13 of 23 of the cell lines tested. Mutation of the p53 gene was significantly associated with high levels of expression of the p53 protein. The average ID(50) (drug dose required to inhibit 50% of cell growth) for cell lines with mutant p53 was 6.8 microM, whereas the average ID(50) for cell lines with wild-type p53 was 13.7 microM. CONCLUSIONS: These in vitro data support a role for mutation of the p53 tumor suppressor gene as a marker for response to cisplatin in HNSCC. Copyright 2003 Wiley Periodicals, Inc.
BACKGROUND: A critical factor for successful organ preservation treatment in head and neck cancer may be selecting tumors that respond to chemotherapy and radiation. Previous results in patients indicated that tumors that overexpressed p53 were more sensitive to chemotherapy than those that did not overexpress p53. METHODS: To determine the relationship of p53 mutations to sensitivity to cisplatin in vitro, 23 head and neck squamous cell carcinoma (HNSCC) cell lines were analyzed for cisplatin sensitivity, p53 expression, and p53 mutation status. RESULTS: Mutations of the p53 gene were identified in 13 of 23 of the cell lines tested. Mutation of the p53 gene was significantly associated with high levels of expression of the p53 protein. The average ID(50) (drug dose required to inhibit 50% of cell growth) for cell lines with mutant p53 was 6.8 microM, whereas the average ID(50) for cell lines with wild-type p53 was 13.7 microM. CONCLUSIONS: These in vitro data support a role for mutation of the p53tumor suppressor gene as a marker for response to cisplatin in HNSCC. Copyright 2003 Wiley Periodicals, Inc.
Authors: Jie Yang; Donna McEachern; Wenyan Li; Mary A Davis; Hua Li; Meredith A Morgan; Longchuan Bai; Jonathan T Sebolt; Haiying Sun; Theodore S Lawrence; Shaomeng Wang; Yi Sun Journal: Mol Cancer Ther Date: 2011-01-31 Impact factor: 6.261
Authors: Magdy E Mahfouz; Juan P Rodrigo; Robert P Takes; Mohamed N Elsheikh; Alessandra Rinaldo; Ruud H Brakenhoff; Alfio Ferlito Journal: Eur Arch Otorhinolaryngol Date: 2010-06 Impact factor: 2.503
Authors: Frank Ziemann; Andrea Arenz; Stefanie Preising; Claus Wittekindt; Jens P Klussmann; Rita Engenhart-Cabillic; Andrea Wittig Journal: Am J Cancer Res Date: 2015-02-15 Impact factor: 6.166
Authors: Vlad C Sandulache; Heath D Skinner; Thomas J Ow; Aijun Zhang; Xuefeng Xia; James M Luchak; Lee-Jun C Wong; Curtis R Pickering; Ge Zhou; Jeffrey N Myers Journal: Cancer Date: 2011-06-30 Impact factor: 6.860
Authors: Osama A Elkashty; Ramy Ashry; Ghada Abu Elghanam; Hieu M Pham; Xinyun Su; Camille Stegen; Simon D Tran Journal: Med Oncol Date: 2018-08-04 Impact factor: 3.064
Authors: Adam Scheel; Emily Bellile; Jonathan B McHugh; Heather M Walline; Mark E Prince; Susan Urba; Gregory T Wolf; Avraham Eisbruch; Francis Worden; Thomas E Carey; Carol Bradford Journal: Laryngoscope Date: 2016-06-27 Impact factor: 3.325